.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,780,986

« Back to Dashboard

Details for Patent: 7,780,986

Title:Method of preparing sustained-release preparations of quinolone antibiotics
Abstract: The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay.
Inventor(s): Kanikanti; Venkata-Rangarao (Leverkusen, DE), Rupp; Roland (Bergisch Gladbach, DE), Weber; Wolfgang (Cologne, DE), Deuringer; Peter (Cologne, DE), Henck; Jan-Olav (Willich, DE), Stab; Heino (Cologne, DE), Nishioka; Takaaki (Nabari, JP), Katakawa; Yoshifumi (Kusatsu, JP), Taniguchi; Chika (Nishinomiya, JP), Ichihashi; Hitoshi (Suita, JP)
Assignee: Bayer Schering Pharma AG (Leverkusen, DE)
Filing Date:Nov 16, 2006
Application Number:11/560,594
Claims:1. A process for the production of an orally administrable antibiotic matrix preparation comprising a mixture of a salt with the free base of a quinolone active compound at a salt-to-free base weight ratio of from 1:10 to 10:1, wherein the preparation releases 80% of the active compound both in 0.1 N hydrochloric acid and in acetate buffer at pH 4.5 in the USP XXIV paddle test at 50 revolutions per minute/37.degree. C. in the course of 1 to 4 hours, and wherein the preparation is a combination preparation comprising a rapid-release (IR) part and a delayed release (CR) part, according to which one part of the active compound is mixed with disintegrant, granulated and mixed with glidant and lubricant (IR part), and another part of the active compound is mixed with acid and a gel-forming polymer, granulated and mixed with glidant and lubricant (CR part), and IR part and CR part are tabletted to give combination tablets and the resulting tablets are coated.

2. The process of claim 1, wherein the salt-to-free base weight ratio is from about 1.3:1 to about 1.8:1.

3. The process of claim 1, wherein the quinolone active compound is ciprofloxacin.

4. The process of claim 3, wherein the salt and free base are ciprofloxacin hydrochloride and ciprofloxacin betaine, respectively.

5. The process of claim 1, wherein the gel-forming polymer is selected from the group consisting of alkylcellulose, hydroxyalkylcellulose, and carboxyalkylcellulose and its alkali metal salts.

6. The process of claim 5, wherein the gel-forming polymer is a hydroxyalkylcellulose.

7. The process of claim 5, wherein the gel-forming polymer is a crosslinked carboxymethylcellulose or an alkali metal salt thereof.

8. The process of claim 6, wherein the gel-forming polymer is hydroxypropylmethylcellulose of a viscosity of at most 75 cP, measured as a 2% strength by weight aqueous solution at 20.degree. C.

9. The process of claim 8, wherein the hydroxypropylmethylcellulose has a viscosity of at most 50 cP, measured as a 2% strength by weight aqueous solution at 20.degree. C.

10. The process of claim 1, wherein the acid is an organic acid having from 2 to 10 carbon atoms and from 1 to 4 carboxyl groups.

11. The process of claim 10, wherein the organic acid is selected from the group consisting of acetic acid, malonic acid, succinic acid, fumaric acid, tartaric acid and citric acid.

12. The process of claim 10, wherein the organic acid is succinic acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc